Search

Search Constraints

You searched for: Author/Creator Symeonidis, Argiris

Search Results

1. Occupational, dietary, and other risk factors for myelodysplastic syndromes in Western Greece. Issue 7 (9th August 2017)

2. The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry. (21st March 2019)

3. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Issue 12 (December 2018)

4. Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis. (August 2021)

5. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5‐azacytidine—data from the Hellenic myelodysplastic syndrome study group. Issue 2 (1st January 2021)

6. Cover Image. Issue 2 (13th April 2021)

7. Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine. Issue 3 (23rd February 2022)

8. Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. Issue 8 (2nd August 2021)

9. Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial. Issue 4 (6th February 2022)

10. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Issue 2 (February 2022)